Psychiatr. praxi 2017; 18(3): 106-113 | DOI: 10.36290/psy.2017.020

Current trends in treatment of anxiety disorders

MUDr. Eliška Nosková1, MUDr. Pavla Stopková, Ph.D.1,2, MUDr. Antonín Šebela1,3
1 Národní ústav duševního zdraví, Klecany
2 3. lékařská fakulta UK, Praha
3 1. lékařská fakulta UK, Praha

Anxiety disorders are a group of mental disorders, characterised by significant feelings of anxiety, usually accompanied by physicalsymptoms. Anxiety is induced either by specific and well-defined situations, or occurs without any apparent stimulus. In ourpaper, we review current trends and treatment guidelines of pharmacotherapy, psychotherapy, and additional evidence-basedtherapeutic interventions. Primarily, we focus on the most common disorders, such as social anxiety disorder, agoraphobia, panicdisorder, generalized anxiety disorder and specific phobias. Moreover, we also discuss briefly other disorders, e. g. obsessive–compulsivedisorder and stress-related disorders, which are in the DSM-5 classified as adjoining chapters. In conclusion, we overviewrecent trends and current clinical research, that offer future therapeutic possibilities.

Keywords: anxiety, neuropsychopharmacology, psychotherapy, exercise

Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nosková E, Stopková P, Šebela A. Current trends in treatment of anxiety disorders. Psychiatr. praxi. 2017;18(3):106-113. doi: 10.36290/psy.2017.020.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Michelle G Craske, Murray B Stein; Anxiety; Lancet 2016; 388: 3048-3059. Go to original source...
    2. Levitan MN, Papelbaum M, Nardi AE. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder; Neuropsychiatric Disease and Treatment 2015; 11: 1149-1115. Go to original source...
    3. Ronald C, Kessler, et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative; World Psychiatry 2007; 6: 168-176.
    4. Baxter AJ, Scott KM, Vos T, Whiteford HA. Global prevalence of anxiety disorders: a systematic review and meta-regression Psychological Medicine 2013; 43: 897-910. Go to original source... Go to PubMed...
    5. Olesen L, et al. The economic cost of brain disorders in Europe; European Journal of Neurology 2012; 19: 155-162. Go to original source...
    6. Muscatello MR, et al. Clinically relevant drug interactions in anxiety disorders; Hum. Psychopharmacol Clin Exp (2012). Go to original source...
    7. Rickels K, et al. Remission of Generalized Anxiety Disorder after 6 Months of Open-Label Treatment with Venlafaxine XR; Psychother Psychosom 2013; 82: 363-371. Go to original source...
    8. Katzman MA, Jacobs L. Venlafaxine in the treatment of panic disorder; Neuropsychiatric Disease and Treatment 2007; 3(1): 59-67. Go to original source... Go to PubMed...
    9. Joint Formulary Committee (2012) British National Formulary (BNF) 65. London: BMJ Publishing Group Ltd and Royal Pharmaceutical.
    10. Katzma MA, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders; BMC Psychiatry 2014; 14(Suppl 1): S1. Go to original source... Go to PubMed...
    11. Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders: a meta-analysis; J Affect Disord 2010; 123: 9-16. Go to original source... Go to PubMed...
    12. Donovan MR, et al. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders: A meta-analysis; Journal of Affective Disorders 2010; 123: 9-16. Go to original source... Go to PubMed...
    13. Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks.; J Clin Psychiatry. 1987; 48(2): 55-59.
    14. Blanco C, Bragdon LB, Schneier FR, et al. The evidence-based pharmacotherapy of social anxiety disorder; Int J Neuropsychopharmacol 2013; 16: 235-249. Go to original source... Go to PubMed...
    15. Ross DC, Klein DF, Uhlenhuth EH. Improved statistical analysis of moclobemide dose effects on panic disorder treatment; EurArch Psychiatry Clin Neurosci 2010; 260: 243-248. Go to original source...
    16. David S. Baldwin, et al. Evidence-based pharmacological treatment of generalized anxiety disorder; International Journal of Neuropsychopharmacology 2011; 14: 697-710. Go to original source... Go to PubMed...
    17. Pande A, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study; J Clin Psychopharmacol 2004; 24: 141-149. Go to original source... Go to PubMed...
    18. Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study; Int Clin Psychopharmacol 2011; 26: 213-220. Go to original source... Go to PubMed...
    19. Stein DJ, Baldwin DS, Baldinetti F, et al. (2008b) Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies; Eur Neuropsychopharmacol 2008; 18: 422-430. Go to original source... Go to PubMed...
    20. Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder; Int J Neuropsychopharmacol 2013; 16: 925-936. Go to original source... Go to PubMed...
    21. Montgomery S, Emir B, Haswell H, et al. Long-term treatment of anxiety disorders with pregabalin: A 1 year open-label study of safety and tolerability; Curr Med Res Opin 2013; 29: 1223-1230. Go to original source... Go to PubMed...
    22. Baldwin DS, Ajel K, Masdrakis VG, et al. Pregabalin for the treatment of generalized anxiety disorder: An update. Neuropsychiatr DisTreat 2013; 9: 883-892. Go to original source... Go to PubMed...
    23. Chessick CA, Allen HA, Thase ME, et al. Azapirones for generalized anxiety disorder; Cochrane Database Syst Rev 19, 2006: CD006115. Go to original source... Go to PubMed...
    24. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia; J Affect Disord 1996; 39: 115-121. Go to original source... Go to PubMed...
    25. Narong Maneeton, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials; Drug Design, Development and Therapy 2016; 10: 259-276. Go to original source... Go to PubMed...
    26. Prosser JM, Yard S, Steele A, Cohen LJ, Galynker II. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study; BMC Psychiatry 2009; 9: 25. Go to original source... Go to PubMed...
    27. Nienke CC, Vulink, et al. Review of atypical antipsychotics in anxiety; European Neuropsychopharmacology 2011; 21: 429-449. Go to original source... Go to PubMed...
    28. Fineberg NA, Brown A, Reghunandanan S, et al. Evidence-based pharmacotherapy of obsessive-compulsive disorder; Int J Neuropsychopharmacol 2012; 15: 1173-1191. Go to original source... Go to PubMed...
    29. Rosario B. Hidalgo, et al. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder; Journal of Psychopharmacology 2007; 21(8): 864-872. Go to original source... Go to PubMed...
    30. Pim Cuijpers, et al. How effective are cognitive behavior therapies for major depression and anxiety disorders? A meta-analytic update of the evidence; World Psychiatry 2016; 15: 245-258. Go to original source... Go to PubMed...
    31. Loerinc AG, et al. Response rates for CBT for anxiety disorders: need for standardized criteria; Clin. Psychol. Rev. 2015; 42: 72-82. Go to original source... Go to PubMed...
    32. Wolitzky-Taylor KB, Horowitz JD, Powers MB, et al. Psychological approaches in the treatment of specific phobias: A meta-analysis. Clin Psychol Rev 2008; 28: 1021-1037. Go to original source... Go to PubMed...
    33. Alamy S, Wei Z, Varia I, et al. Escitalopram in specific phobia: Results of a placebo-controlled pilot trial; J Psychopharmacol 2008; 22: 157-161. Go to original source... Go to PubMed...
    34. Kaushadh Jayakody, et al. Exercise for anxiety disorders: systematic review; Br J Sports Med 2014; 48: 187-196. Go to original source... Go to PubMed...
    35. Broocks A, Bandelow B, Pekrun G, et al. Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder; Am J Psychiatry 1998; 155: 603-609. Go to original source... Go to PubMed...
    36. Sexton H, Maere A, Dahl NH. Exercise intensity and reduction in neurotic symptoms; Acta Psychiatrica Scandinavica 1989; 80: 231-235. Go to original source... Go to PubMed...
    37. Esquivela G, Diaz-Galvisb J, Schrusersa K, et al. Acute exercise reduces the effects of a 35% CO2 challenge in patients with panic disorder; J Affect Disord; 2008; 107: 217-220. Go to original source... Go to PubMed...
    38. Martinsen EW, Hoffart A, Solberg Y. Aerobic and non-aerobic forms of exercise in the treatment of anxiety disorders; Stress Med 1989; 5: 115-120. Go to original source...
    39. Christine A. Bartley et al.; Meta-analysis: Aerobic exercise for the treatment of anxiety disorders; Progress in Neuro-Psychopharmacology & Biological Psychiatry 45 (2013) 34-39 Go to original source... Go to PubMed...
    40. Carl Gommoll MS, et al. Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo controlled, flexible-dose study; International Clinical Psychopharmacology 2015; 30: 297-306. Go to original source... Go to PubMed...
    41. Carl Gommoll MS, et al. A double-blind, randomized, placebo-controlled, fixed-does phase III study of vilazodone in patients with generalized anxiety; Depression and anxiety 2015; 32: 451-459. Go to original source... Go to PubMed...
    42. Stein DJ, Ahokas A, Albarran C, et al. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73: 1002-1008. Go to original source... Go to PubMed...
    43. Dan J. Stein et al. Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A12-week, double-blind, placebo-controlled study; European Neuropsychopharmacology 2017; 27: 526-537. Go to original source...
    44. McAllister-Williams RH, Baldwin DS, Haddad PM, et al. The use of antidepressants in clinical practice: focus on agomelatine; HumPsychopharmacol 2010; 25: 95-102. Go to original source... Go to PubMed...
    45. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder; J Clin Psychiatry. 2002; 63: 31-37. Go to original source... Go to PubMed...
    46. Richardson R, Ledgerwood L, Cranney J. Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications; Learning and Memory 2004; 11(5): 510-516. Go to original source... Go to PubMed...
    47. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al. D-cycloserine augmentated exposure therapy for obsessive-compulsive disorder; BiologicalPsychiatry 2007; 62(9): 835-838. Go to original source... Go to PubMed...
    48. Ori R, et al. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders (Review); Cochrane Database of Systematic Reviews 2015; Issue 5. Art. No.: CD007803. Go to original source...
    49. Webb AJS, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 2010; 375: 906-915. Go to original source... Go to PubMed...
    50. Steenen SA, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis; Journal of Psychopharmacology 2016; 30(2): 128-139. Go to original source... Go to PubMed...
    51. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks; J Clin Psychopharmacol 1989; 9: 22-27. Go to original source... Go to PubMed...
    52. Siegfried Kasper, et al. Silexan in anxiety disorders: Clinical data and pharmacological background; The world journal of biological psychiatry, 2017; DOI: 10.1080/15622975.2017.1331046 Go to original source... Go to PubMed...
    53. Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review; Int J Psychiatry Clin Pract 2013; 17(Suppl 1): 15-22. Go to original source... Go to PubMed...
    54. Savage KM, et al. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial; Trials 2015; 16: 493. Go to original source... Go to PubMed...
    55. Klein B, et al. Internet-Based Treatment for Panic Disorder: Does Frequency of Therapist Contact Make a Difference?; Cognitive Behaviour Therapy 2009; 38(2): pp. 100-113. Go to original source... Go to PubMed...
    56. Olthuis JV, Watt MC, Bailey K, Hayden JA, Stewart SH. Therapist-supported Internet cognitive behavioural therapy for anxiety disorders in adults (Review); Cochrane Database of Systematic Reviews 2016; Issue 3. Art. No.: CD011565. Go to original source...
    57. Diefenbach GJ, et al. Repetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial; The British Journal of Psychiatry 2016; 209: 222-228. Go to original source... Go to PubMed...
    58. Bystritsky A, Kaplan JT, Feusner JD, Kerwin LE, Wadekar M, Burock M, Wu AD, Iacoboni M. A preliminary study of fMRI-guided rTMS in the treatment of generalized anxiety disorder; J Clin Psychiatry 2008; 69: 1092-1098. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.